Market Research Report
Hemophilia Market Size, Share & Trends Analysis Report By Type (Type A, Type B, Type C), By Treatment (On-demand, Prophylaxis), By Therapy (Replacement Therapy, Gene Therapy), By Region, And Segment Forecasts, 2020 - 2027
|Published by||Grand View Research, Inc.||Product code||368045|
|Published||Content info||90 Pages
Delivery time: 2-3 business days
|Hemophilia Market Size, Share & Trends Analysis Report By Type (Type A, Type B, Type C), By Treatment (On-demand, Prophylaxis), By Therapy (Replacement Therapy, Gene Therapy), By Region, And Segment Forecasts, 2020 - 2027|
|Published: March 13, 2020||Content info: 90 Pages||
The global hemophilia market size is expected to reach USD 18.1 billion by 2027, according to a new report by Grand View Research, Inc. It is anticipated to register a CAGR of 5.5% over the forecast period. Increasing awareness of early diagnosis and treatment coupled with supportive government policies is anticipated to boost market share over the forecast period.
For instance, the NHF (National Hemophilia Foundation) allows to find treatments for inheritable bleeding disorders and help prevent complications of these disorders through research, education, and advocacy. Their programs and initiatives are in association with the Centers for Disease Control and Prevention.
In addition, U.S. Hemophilia Treatment Center Network provides specialized healthcare centers and these offer care to address all psychological, educational, and physical needs of patients suffering from the disease. These centers currently provide care to more than 35,000 adults and children with the disease and other bleeding disorders.
The key market companies are projected to adopt strategic initiatives including geographic expansion and R&D especially in developing and underdeveloped regions, such as Middle Eastern and West African countries.
For instance, BioMarin is involved in developing Valoctocogene Roxaparvovec (BMN-270) for treating type A patients and is currently under clinical trials. Furthermore, in June 2017, the U.S. FDA accepted the investigational new drug application for Sanofi's BIVV001 based on its preclinical study results.
Rising incidence of the disease is estimated to propel hemophilia market growth over the forecast period. According to the data published by the NHF, around 20,000 individuals in U.S. are suffering from this disease. In addition, approximately 75% of people with hemophilia receive inadequate treatment or have less/ no access to treatment globally.
Further key findings from the report suggest:
Hemophilia A held the largest market share in 2019 due to its increasing prevalence worldwide
Type B is expected to be the fastest growing type over the forecast period, at a CAGR of 6.8%
On-demand dominated the treatment segment over the forecast period and is expected to contribute majority of the share in 2019
Prophylaxis is estimated to be the fastest growing segment over the forecast period
Replacement therapy was expected to be the largest segment in 2019
Gene therapy dominated the therapy segment over the forecast period owing to increasing involvement of companies to develop more gene therapy for its treatment
Increasing research and development and strategic collaborations are key strategies undertaken by major players in the market space.